Improvement in patient global impression measures with upadacitinib with or without topical corticosteroids in moderate to severe atopic dermatitis: Results from placebo-controlled phase 3 studies
Recommended Citation
Gooderham M, Deleuran M, Gold LS, Calimlim B, Zeng J, Takemoto S, Raymundo E, and Weidinger S. Improvement in patient global impression measures with upadacitinib with or without topical corticosteroids in moderate to severe atopic dermatitis: Results from placebo-controlled phase 3 studies. Exp Dermatol 2021; 30:16-17.
Document Type
Conference Proceeding
Publication Date
11-1-2021
Publication Title
Exp Dermatol
Abstract
Introduction: Atopic dermatitis (AD) is associated with symptoms that impact patients’ quality of life. We assessed improvements in patient global impression measures with upadacitinib (UPA) versus placebo (PBO) using data from three moderate-to-severe AD trials.
Methods: Patients (age 12-75 years) with moderate-to-severe AD were randomized 1:1:1 to once-daily UPA 15 mg, 30 mg, or PBO without concomitant topical corticosteroids (Measure Up 1 [NCT03569293], Measure Up 2 [NCT03607422]) or with concomitant topical corticosteroids (AD Up [NCT03568318]) for 16 weeks. Overall symptom severity, symptom improvement, and treatment satisfaction were assessed by the Patient Global Impression of Severity (PGIS), Patient Global Impression of Change (PGIC), and Patient Global Impression of Treatment (PGIT) questionnaires, respectively.
Results: On the PGIS, greater proportions of patients reported that their symptoms were “absent/minimal” with UPA 15 mg/30 mg versus PBO as early as the first post-baseline study visit (week 1 for Measure Up 1 and 2; week 2 for AD Up) and through to week 16 (Measure Up 1: 43.5%/59.6% versus 8.3%; Measure Up 2: 38.6%/53.1% versus 6.7%; AD Up: 42.9%/55.7% versus 9.3%; p < 0.001). Similarly, on the PGIC, greater proportions of patients reported that their disease was “much improved/very much improved” as early as week 1 (week 2 for AD Up) and through to week 16 (Measure Up 1: 70.0%/79.8% versus 19.7%; Measure Up 2: 66.3%/76.3% versus 15.8%; AD Up: 73.6%/82.3% versus 28.8%; p < 0.001). Treatment satisfaction results were consistent, with more patients reporting that they were “very satisfied/extremely satisfied” in the UPA 15 mg/30 mg arms versus PBO as early as week 1 (week 2 for AD Up) and through to week 16 (Measure Up 1: 54.3%/60.0% versus 12.3%; Measure Up 2: 47.6%/57.1% versus 10.4%; AD Up: 53.7%/64.7% versus 18.7%; p < 0.001).
Discussion: More patients reported no/minimal AD symptoms, much improved disease, and high levels of treatment satisfaction with UPA (15 mg or 30 mg) versus PBO, with or without concomitant topical corticosteroids, across all study visits throughout the 16-week period.
Volume
2021
Issue
30
First Page
16
Last Page
17
